云顶新耀战略投资天境生物，管线、临床能力、资源配置等多方位协同可期

交银国际08-05

一、战略投资天境生物云顶新耀参与天境生物增发，以每ADS1.95美元的对价认购总代价约为3,090万美元的新股，成为后者的单一最大股东。通过此次战略投资，公司有机会利用天境差异化的4-1BB平台、双抗管线及海外临床转化能力，与其现有的mRNA肿瘤疫苗布局形成协同。二、天境生物研发亮点天境生物拥有包括Givastomig（Claudin18.2/4-1BB双抗）和Ragistomig（PD-L1/4...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2557364788?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-05 17:13","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2557364788","market":"us","top_or_hot":-1,"title":"云顶新耀战略投资天境生物，管线、临床能力、资源配置等多方位协同可期","media":"交银国际","content":"<div>\n<p>一、战略投资天境生物云顶新耀参与天境生物增发，以每ADS1.95美元的对价认购总代价约为3,090万美元的新股，成为后者的单一最大股东。通过此次战略投资，公司有机会利用天境差异化的4-1BB平台、双抗管线及海外临床转化能力，与其现有的mRNA肿瘤疫苗布局形成协同。二、天境生物研发亮点天境生物拥有包括Givastomig（Claudin18.2/4-1BB双抗）和Ragistomig（PD-L1/4...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805173038a6d437ba&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>云顶新耀战略投资天境生物，管线、临床能力、资源配置等多方位协同可期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n云顶新耀战略投资天境生物，管线、临床能力、资源配置等多方位协同可期\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-05 17:13 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805173038a6d437ba&s=b><strong>交银国际</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>一、战略投资天境生物云顶新耀参与天境生物增发，以每ADS1.95美元的对价认购总代价约为3,090万美元的新股，成为后者的单一最大股东。通过此次战略投资，公司有机会利用天境差异化的4-1BB平台、双抗管线及海外临床转化能力，与其现有的mRNA肿瘤疫苗布局形成协同。二、天境生物研发亮点天境生物拥有包括Givastomig（Claudin18.2/4-1BB双抗）和Ragistomig（PD-L1/4...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805173038a6d437ba&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805173038a6d437ba&s=b","article_id":"2557364788","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805173038a6d437ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2557364788","pubTimestamp":1754385223,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"通过此次战略投资，公司有机会利用天境差异化的4-1BB平台、双抗管线及海外临床转化能力，与其现有的mRNA肿瘤疫苗布局形成协同。云顶新耀在交银国际覆盖的生物科技公司中占据重要位置，未来有望受益于医药行业的整体发展和自身的突破性进展。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","BK4535":"淡马锡持仓","BK4526":"热门中概股","01952":"云顶新耀","BK4505":"高瓴资本持仓"},"translate_title":"Genting Xinyao strategically invests in Tianjing Biotech, and multi-faceted synergy in pipelines, clinical capabilities, and resource allocation can be expected","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMAB":0.9,"01952":0.9},"content_text":"一、战略投资天境生物云顶新耀参与天境生物增发，以每ADS1.95美元的对价认购总代价约为3,090万美元的新股，成为后者的单一最大股东。通过此次战略投资，公司有机会利用天境差异化的4-1BB平台、双抗管线及海外临床转化能力，与其现有的mRNA肿瘤疫苗布局形成协同。二、天境生物研发亮点天境生物拥有包括Givastomig（Claudin18.2/4-1BB双抗）和Ragistomig（PD-L1/4-1BB双抗）在内的差异化肿瘤靶向/免疫疗法管线。Givastomig联合O药和化疗正用于一线胃癌治疗的探索，在美国Ib期研究中展现出优于当前一线胃癌标准疗法的数据。Ragistomig在分子设计上有差异化，仅在肿瘤微环境中结合PD-L1并激活4-1BB，其I期数据显示ORR和DCR优于同靶点竞品。三、未来催化剂与目标价交银国际维持云顶新耀买入评级，并设72.5港元的目标价。未来潜在催化剂包括基于mRNA平台自主开发的EVM14完成启动入组、自体生成CAR-T完成临床前概念验证并启动IIT研究、Givastomig联用方案剂量扩展阶段数据读出以及更完整的单药方案数据等。此外，预计公司在2026年实现盈利，市盈率将降至合理水平。四、财务表现与估值云顶新耀预计2025年至2027年的收入增长率分别为134.9%、53.7%和47.1%，对应净利润将从亏损转为盈利。公司目前市值为202亿港元，市账率为4.74倍。分析师认为公司的全球化战略布局和现有资产的全球价值将逐步显现，长期看好其市场表现。五、行业覆盖情况交银国际同时覆盖了多家生物科技公司，如三生制药、康方生物、信达生物等，给予这些企业不同的评级和目标价。云顶新耀在交银国际覆盖的生物科技公司中占据重要位置，未来有望受益于医药行业的整体发展和自身的突破性进展。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557364788","isCrawlerRequest":true}